SITC 2026: UT MD Anderson highlights advances in cancer immunotherapy
ABSTRACTS: 241, 566, 828, 931, 1180
Researchers from The University of Texas MD Anderson Cancer Center highlighted promising advances in cancer immunotherapy at the 2026 Society for Immunotherapy of Cancer (SITC) Annual Meeting. The presentations showcased early-phase clinical trials and preclinical studies exploring new approaches to treating advanced cancers, including solid tumors, brain cancer and melanoma. These studies offer...
Randomized trial finds targeting individual metastases in oligometastatic breast cancer does not improve survival
Oligometastatic cancer has spread beyond the original tumor to a limited number of sites Study tested whether treating all visible...
Fecal microbiota transplantation may improve immunotherapy-related colitis
Most patients with appendix cancer may avoid chemotherapy after surgery, study suggests
Most patients with localized appendix cancer may be able to safely avoid chemotherapy after surgery, according to a new study from researchers at The University of...
KRAS-targeting drugs show promise for rare appendix cancer
ASCO: Targeted therapy combo nearly doubles time without disease progression for patients with advanced colorectal cancer
ASCO: UT MD Anderson spotlights emerging precision therapies for rare and difficult-to-treat cancers
ABSTRACTS: 8510, 8008, 6009, 4520
Researchers at The University of Texas MD Anderson Cancer Center will present new findings at the...
Tumor markers in rare appendiceal cancer may predict treatment outcomes
New simulation framework DKOsim advances CRISPR-based gene to gene interaction research
Double-CRISPR Knockout Simulation (DKOsim) is a computer-based “virtual lab” that simulates genomic experiments Studying...
Low testosterone levels may be associated with increased risk of prostate cancer progression during surveillance
Study found men with low testosterone levels were associated with a 60% higher likelihood that prostate cancer...
Mutation predicts chemotherapy resistance and better responses to immunotherapy in advanced bladder cancer
Immunotherapy combination does not improve outcomes for patients with advanced anal cancer
Targeted therapy plus immunotherapy improved outcomes in advanced metastatic colorectal cancer
Study identifies target for disease hyper progression after immunotherapy in kidney cancer
HER2-targeted therapy shows promising results in rare bile duct cancers
Researchers identify rare mutation that predicts strong immunotherapy response in colorectal cancer
MD Anderson experts spotlight key immunotherapy advances at 2025 SITC Annual Meeting
Comprehensive molecular profiling of renal medullary carcinoma identifies TROP2 as a promising therapeutic target
Researchers at The University of Texas MD Anderson Cancer Center, in collaboration with BostonGene, conducted the largest and most comprehensive...
New oral therapy shows early signs of safety and effectiveness in patients with advanced, treatment-resistant prostate cancer
ESMO 2025: Dual targeted therapy shows promise in previously treated advanced kidney cancer patients